

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DA	E FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/622,011	07/16/200	Julie D. Saba	200116.405C1	1654	
500	7590 01	11/2006	EXAM	EXAMINER	
SEED INTE	ELLECTUAL P	CHOWDHURY, I	CHOWDHURY, IQBAL HOSSAIN		
SUITE 6300		ART UNIT	PAPER NUMBER		
SEATTLE,	WA 98104-7092	1652			

DATE MAILED: 01/11/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/622,011	SABA, JULIE D.				
Office Action Summary	Examiner	Art Unit				
	Iqbal Chowdhury, Ph.D.	1652				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
3) Since this application is in condition for allowar	action is non-final. nce except for formal matters, pro					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) ⊠ Claim(s) 1-31 is/are pending in the application. 4a) Of the above claim(s) is/are withdray 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) 1-31 are subject to restriction and/or expressions.	vn from consideration.					
Application Papers						
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine	epted or b) objected to by the bed drawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Do 5) Notice of Informal P 6) Other:					

Application/Control Number: 10/622,011 Page 2

Art Unit: 1652

DETAILED ACTION

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

1. Claims 1-7, 12-15, 16-19, 20-26, and 27-31, drawn to a method for identifying an

agent that modulates sphingolipid metabolism comprising altered growth of the

mutant yeast strain and a decrease of SPHK1 activity, classified in class 435,

subclass 29.

II. Claims 8-11, drawn to a method for identifying an inhibitor of sphingosine kinase

comprising altered growth of a null mutant yeast strain, classified in class 435,

subclass 15.

For each of inventions I-II above, restriction to one of the following is also required

under 35 USC121. Therefore, election is required of one of inventions I-II and one of inventions

(A)-(C).

(A). methods of utilizing a null mutant of the DPL1 gene.

(B) methods utilizing a null mutant of the DPL1 and LCB4 genes.

(C), methods utilizing a null mutant of the DPL1, LCB4 and YSR2 genes.

The inventions are distinct, each from the other because of the following reasons:

2. The methods of groups I-II are patentably distinct as they comprise unrelated steps, as

use different products and produce different effects.

3. The mutants of Group (A)-(C) are unrelated. Inventions are unrelated if it can be shown

that they are not disclosed as capable of use together and they have different modes of operation,

Art Unit: 1652

different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions represent genetically distinct microorganisms with distinct functional characteristics.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37CFR 1.48b if one or more of the currently named inventors are no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under CFR 1.48 (b) and by the fee required under 37 CFR 1.17 (i).

Applicant is advised the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Iqbal H. Chowdhury whose telephone number is 571-272-8137. The examiner can normally be reached on 9:00-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 703-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Respectfully,

Application/Control Number: 10/622,011

Art Unit: 1652

Iqbal Chowdhury, PhD, Patent Examiner Art Unit 1652 (Recombinant Enzymes) US Patent and Trademark Office Remsen Bldg., Rm. 2B69, Mail Box. 2C70 Ph. (571)-272-8137, Fax. (571)-273-8137 IC

REBECCA E. PROUTY
PRIMARY EXAMINEN
GROUP 1800